DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.

@article{Lemaistre2000DAB389IL2D,
  title={DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.},
  author={Charles Fred Lemaistre},
  journal={Clinical lymphoma},
  year={2000},
  volume={1 Suppl 1},
  pages={S37-40}
}
DAB(389)IL-2 (denileukin diftitox, ONTAK) is an interleukin-2 receptor (IL-2R)-specific ligand fusion protein that may potentially be selective for IL-2R-expressing malignancies. The activity of DAB(389)IL-2 in the treatment of cutaneous T-cell lymphoma has established the feasibility of utilizing such a targeted therapeutic in disseminated disease with acceptable toxicity. Data from the phase I trial suggest that the definition of activity in other cancer types, including other non-Hodgkin's… CONTINUE READING